{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:30Z","timestamp":1793946510558,"version":"4.8.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1194703"],"award-info":[{"award-number":["1194703"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2016274"],"award-info":[{"award-number":["2016274"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eclinm.2026.104207","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:53:26Z","timestamp":1791212006000},"page":"104207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2364-324X","authenticated-orcid":false,"given":"Chi Kin","family":"Law","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Stockler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9066-8244","authenticated-orcid":false,"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael L.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.eclinm.2026.104207_bib1","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104207_bib2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/pcan.2016.30","article-title":"Increasing incidence of metastatic prostate cancer in the United States (2004-2013)","volume":"19","author":"Weiner","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104207_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.33787","article-title":"Cost-effectiveness of prostate radiation therapy for men with newly diagnosed low-burden metastatic prostate cancer","volume":"4","author":"Lester-Coll","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104207_bib4","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/ERC-18-0289","article-title":"Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond","volume":"26","author":"Linder","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104207_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm972","article-title":"Molecular determinants of resistance to antiandrogen therapy","volume":"10","author":"Chen","year":"2004","journal-title":"Nat Med"},{"issue":"32","key":"10.1016\/j.eclinm.2026.104207_bib6","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","article-title":"Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis","volume":"23","author":"Scher","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104207_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104207_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2026.104207_bib9","article-title":"Adding enzalutamide to first-line treatment for metastatic hormone-sensitive prostate cancer: a cost-effectiveness analysis","volume":"9","author":"Zhang","year":"2021","journal-title":"Front Public Health"},{"key":"10.1016\/j.eclinm.2026.104207_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.627083","article-title":"A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer","volume":"11","author":"Sung","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104207_bib11","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.euo.2023.11.013","article-title":"Cost effectiveness of systemic treatment intensification for metastatic hormone-sensitive prostate cancer: is triplet therapy cost effective?","volume":"7","author":"Sathianathen","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104207_bib12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.36469\/jheor.2023.75208","article-title":"HTA and reimbursement status of metastatic hormone-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, and metastatic castration-resistant prostate cancer treatments in Europe: a patient access landscape review","volume":"10","author":"Bencina","year":"2023","journal-title":"J Health Econ Outcomes Res"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104207_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104207_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40258-013-0035-z","article-title":"A pilot discrete choice experiment to explore preferences for EQ-5D-5L health states","volume":"11","author":"Norman","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.eclinm.2026.104207_bib19","series-title":"Table 39a: Total Health Price Index and Industry-Wide Indexes, 2010-11 to 2020-21, Health Expenditure Australia 2020-21","year":"2022"},{"key":"10.1016\/j.eclinm.2026.104207_bib20","series-title":"3A.1 Overview and rationale of the economic evaluation, Submission structure for submissions requiring evaluation","year":"2016"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104207_bib21","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jval.2018.01.017","article-title":"Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC-does the presence of an explicit threshold affect the ICER proposed?","volume":"21","author":"Wang","year":"2018","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104207_bib22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40273-023-01243-0","article-title":"The use of a discrete choice experiment including both duration and dead for the development of an EQ-5D-5L value set for Australia","volume":"41","author":"Norman","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104207_bib23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40273-017-0582-5","article-title":"Australian utility weights for the EORTC QLU-C10D, a multi-attribute utility instrument derived from the cancer-specific quality of life questionnaire, EORTC QLQ-C30","volume":"36","author":"King","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104207_bib24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","article-title":"Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task Force--6","volume":"15","author":"Briggs","year":"2012","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104207_bib25","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.euo.2024.01.016","article-title":"Risk of fractures and falls in men with advanced or metastatic prostate cancer receiving androgen deprivation therapy and treated with novel androgen receptor signalling inhibitors: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Jones","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:52:28Z","timestamp":1793944348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026004608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":21,"alternative-id":["S2589537026004608"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104207","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104207"}}